Another strategy in the treatment of diabetics is the inhibition of dipeptidyl peptidase-4 (DPP4), which functions as a negative regulator of the incretin hormone glucagon-like peptide-1 (GLP-1) by cleaving a terminal dipeptide from the hormone. This evidence concerns the gene GCG and diabetes mellitus.